在高风险的本地细胞检查中,德斯莫普林素和出血风险:对RCT和观察性研究的更新元分析
Gabriel Sartori Pacini1,2, Vanderlei Carlos Bertuol Junior1,2,3, Renata Asnis Schuchmann1,3,4
1Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Renal failure
|August 31, 2025
概括
在高风险患者中,德斯莫普林 (DDAVP) 可能会减少活检后的出血,特别是在观察性研究中. 需要进一步的研究来证实该患者群体的疗效和安全性.
科学领域:
- 肝脏病学
- 血液学
- 药理学
背景情况:
- 活检带有出血风险,特别是在功能受损的患者中.
- 德斯莫普林 (DDAVP) 有时用于预防,但其有效性尚不确定.
- 接受本地活检的高风险患者需要评估降低出血风险.
研究的目的:
- 系统地审查和分析DDAVP在减少出血并发症方面的疗效.
- 评估DDAVP在患有功能障碍 (eGFR<60毫升/分钟/1. 73米2) 的高风险患者中的效果.
主要方法:
- 随机和观察性研究的系统审查和元分析.
- 搜索了PubMed,EMBASE,Cochrane和临床试验网站,直到2025年4月.
- 使用随机效应模型进行组合风险比率 (RRs);进行子组和敏感性分析.
主要成果:
- 包括九项研究 (n=2470). 整体RR出血为0. 61 (95% CI,0. 33-1.11) 具有很高的异质性.
- 观察性研究显示出显著的出血减少 (RR=0. 52),而RCT则没有 (RR=0. 87).
- 敏感性分析排除了异质性的异常值,并显示了显著的聚合效应 (p < .0001).
结论:
- 整体分析缺乏统计意义,但观察数据和敏感性分析表明DDAVP的潜在保护作用.
- 由于证据的确定性较低,结果是探索性的;需要更大的RCT.
- 进一步的研究应该证实DDAVP的疗效,并更好地描述DDAVP用于预防脏活检出血的安全性.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Kidney Transplant II: Surgical Procedure
75
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
75
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152


